% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{AfsharOromieh:120667,
      author       = {A. Afshar-Oromieh$^*$ and U. Haberkorn$^*$ and C. Zechmann
                      and T. Armor and W. Mier and F. Spohn and N. Debus and T.
                      Holland-Letz$^*$ and J. Babich and C. Kratochwil},
      title        = {{R}epeated {PSMA}-targeting radioligand therapy of
                      metastatic prostate cancer with (131){I}-{MIP}-1095.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {44},
      number       = {6},
      issn         = {1619-7089},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2017-01093},
      pages        = {950 - 959},
      year         = {2017},
      abstract     = {Prostate-specific membrane antigen (PSMA)-targeting
                      radioligand therapy (RLT) was introduced in 2011. The first
                      report described the antitumor and side effects of a single
                      dose. The aim of this analysis was to evaluate toxicity and
                      antitumor activity after single and repetitive
                      therapies.Thirty-four men with metastatic
                      castration-resistant prostate cancer received PSMA-RLT with
                      (131)I-MIP-1095. Twenty-three patients received a second,
                      and three patients a third dose, timed at PSA progression
                      after an initial response to the preceding therapy. The
                      applied doses were separated in three groups: <3.5, 3.5-5.0
                      and >5.0 GBq. Antitumor and side-effects were analyzed by
                      blood samples and other clinical data. Follow-up was
                      conducted for up to 5 years.The best therapeutic effect was
                      achieved by the first therapy. A PSA decline of $≥50\%$
                      was achieved in $70.6\%$ of the patients. The second and
                      third therapies were significantly less effective. There was
                      neither an association between the applied activity and PSA
                      response or the time-to-progression. Hematologic toxicities
                      were less prevalent but presented in a higher percentage of
                      patients with increasing number of therapies. After
                      hematologic toxicities, xerostomia was the second most
                      frequent side effect and presented more often and with
                      higher intensity after the second or third therapy.The first
                      dose of RLT with (131)I-MIP-1095 presented with low side
                      effects and could significantly reduce the tumor burden in a
                      majority of patients. The second and third therapies were
                      less effective and presented with more frequent and more
                      intense side effects, especially hematologic toxicities and
                      xerostomia.},
      cin          = {E060 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)E060-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28280855},
      pmc          = {pmc:PMC5397661},
      doi          = {10.1007/s00259-017-3665-9},
      url          = {https://inrepo02.dkfz.de/record/120667},
}